eli lilly Archives - Vista Partners LLC

From Molecules to Millions: How Eupraxia, Eli Lilly and Merck Navigate the FDA Maze -( $EPRX $LLY $MRK )

by John F. Heerdink, Jr. May 4, 2026 212Views 0Likes

The modern FDA approval maze is becoming less a straight corridor and more a high-speed roundabout—and investors riding with Eupraxia Pharmaceuticals (EPRX), Eli Lilly (LLY) and Merck (MRK) may find that’s exactly where outsized opportunity lives. From Wall Poster to Wall Street…

GLP-1s, Hairlines, and the Almost-Pumpers: Why Modular Medical May Be Ready for Its Close-Up -( $LLY $MODD )

by John F. Heerdink, Jr. May 2, 2026 202Views 0Likes

At this point, glucagon-like peptide-1 drugs, or GLP-1s, have become the market’s favorite lifestyle macro-theme, credited with trimming waistlines, lowering A1Cs, and supposedly reshaping everything from snack aisles to airplane seat designs. Yet in 2026, a new subplot is stealing some headlines:…

Eli Lilly’s Strategic Shopping Spree Signals a New Era in Biotech Consolidation -( $LLY $XBI $IBB )

by John F. Heerdink, Jr. April 29, 2026 185Views 0Likes

In a market where capital efficiency has become the new currency of credibility, Eli Lilly & Co. (LLY) appears to be writing a decidedly modern playbook for growth—one acquisition at a time. The Indianapolis-based pharmaceutical heavyweight has quietly assembled a portfolio of…

Eli Lilly Just Hired an Algorithm: Inside the $2.25 Billion AI Drug Whisperer Deal With Profluent -( $LLY $IBB $XBI )

by John F. Heerdink, Jr. April 29, 2026 299Views 0Likes

Eli Lilly’s (LLY) latest AI move reads less like a side project and more like a statement: the drugmaker is quietly trying to turn biology into software—and it just hired Profluent as one of its lead engineers. Lilly Bets Big On AI-Authored…

The Diabesity Gold Rush: GLP‑1 Giants and a Tiny Patch Pump Hunting for XXL Returns -( $AMGN GS $LLY $MODD $NVO )

by John F. Heerdink, Jr. April 8, 2026 307Views 0Likes

The global “diabesity” market is swelling into a once‑in‑a‑generation opportunity, and Eli Lilly, Novo Nordisk—and now a new class of device innovators like Modular Medical (NASDAQ: MODD)—are still lacing up their running shoes rather than sprinting for the finish line. For investors,…

Tag: eli lilly

From Molecules to Millions: How Eupraxia, Eli Lilly and Merck Navigate the FDA Maze -( $EPRX $LLY $MRK )

GLP-1s, Hairlines, and the Almost-Pumpers: Why Modular Medical May Be Ready for Its Close-Up -( $LLY $MODD )

Eli Lilly’s Strategic Shopping Spree Signals a New Era in Biotech Consolidation -( $LLY $XBI $IBB )

Eli Lilly Just Hired an Algorithm: Inside the $2.25 Billion AI Drug Whisperer Deal With Profluent -( $LLY $IBB $XBI )

The Diabesity Gold Rush: GLP‑1 Giants and a Tiny Patch Pump Hunting for XXL Returns -( $AMGN GS $LLY $MODD $NVO )

Your Guide To Staying Informed In The Markets